Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene, which is mainly
involved in the repair of DNA damage, cell cycle regulation, maintenance of genome …

Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor
outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular …

Background Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting
TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). We …

The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin
derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The …

Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic
complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) …

Immunosuppressive elements within the tumor microenvironment, such as tumor-associated
macrophages (TAM), can present a barrier to successful antitumor responses by cytolytic T …

Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic
response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy …

Abstract Background Nicotinamide N-methyltransferase (NNMT) is overexpressed in various
human tumors and involved in the development and progression of several carcinomas. In …

Background Early-stage triple-negative breast cancer (TNBC) displays clinical and
biological diversity. From a biological standpoint, immune infiltration plays a crucial role in …

Background Pathological complete response (pCR) is associated with improved prognosis
in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear …